Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralatrexate versus erlotinib in previously treated advanced non-small cell lung cancer (PDX-012)
2007-004673-26Phase 2Completed
- Sponsor
- Allos Therapeutics
- Start
- Dec 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Pralatrexate arm with Erlotinib arm (2 arms). Primary endpoint: Overall survival. Started Dec 2007; status: completed.
02
Drugs
pralatrexateerlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-004673-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004673-26.